Phase 1 clinical trial of DT-216 to assess the safety, tolerability, pharmacokinetics, and frataxin (FXN) levels in Friedreich Ataxia

DT-216 is a new molecule to activate transcription of the FXN gene and restore production of the frataxin protein. More specifically, it is a GeneTAC™ gene targeted chimera small molecule designed to specifically target the GAA repeat expansion mutation and restore FXN gene expression.

This is a frst-in-human, Phase 1, study of DT-216. The initial single ascending dose part of the Phase 1 has completed recruitment and we are now beginning the Multiple Ascending Dose (MAD) study. Enrollment will be in cohorts (typically 5-8 people). The first cohort will be enrolled and tested at the first dose, then there will be a review of the safety, then typically several weeks later the next cohort will be enrolled to test the next dose. In the MAD study subjects will treated with a once a week dose over 3 weeks, with regular safety assessments after dosing. The study treatment period includes 3 non-consecutive inpatient stays for a total of 10 nights/11 days. Maximum duration of study participation is approximately 10.5 weeks.

Inclusion criteria:

• Individuals with FA ages 18 to 55 years old (inclusive) at screening
• Genetically confirmed diagnosis of FA with homozygous GAA repeat expansions
• Weight between 90 and 200lbs (approximately)
• Ability to sit upright with thighs together and arms crossed without requiring support on more than two sides
• Ability to perform basic daily care such as feeding yourself and basic personal hygiene with minimal assistance